Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis


Cite item

Full Text

Abstract

Background:Metabolism of oral anticoagulants (OAC) is affected by P-glycoprotein (P-gp)/ CYP3A4 enzyme. However, the P-gp/CYP3A4 inhibitors are unavoidably used with OACs.

Methods:Medline, Cochrane, and Embase were systematically searched for randomized controlled trials and cohort studies from inception till 23rd November, 2022 to assess the safety and effectiveness of OACs when concomitantly used with P-gp/CYP3A4 inhibitors. The primary outcomes were major bleeding and gastrointestinal (GI) bleeding. Secondary outcomes were stroke/systemic embolism (SE), all-cause mortality, any bleeding as well as intracranial hemorrhage (ICH). We estimated summary odds ratios (OR) with 95% credible intervals (CI) using pairwise and network meta-analysis with random effects

Results:A total of 11 studies involving 37,973 patients were included. When concomitantly used with P-pg/ CYP3A4 inhibitors, network meta-analysis indicated that dabigatran, apixaban, and edoxaban were associated with significantly lower risk of major bleeding compared to rivaroxaban, with ORs of 0.56, 0.51 and 0.48, respectively. Rivaroxaban and dabigatran were associated with a significantly increased risk of GI bleeding than warfarin, apixaban and edoxaban. Dabigatran and apixaban were linked with significantly lower risk of any bleeding compared with warfarin (ORs were 0.75 and 0.68, respectively) or rivaroxaban (ORs were 0.67 and 0.60, respectively). Apixaban (OR 0.32) and edoxaban (OR 0.35) were associated with a lower risk of ICH compared with warfarin. There was no difference between any OACs in terms of stroke/SE or all-cause mortality.

Conclusion:When concomitantly used with P-gp/CYP3A4 inhibitors, apixaban and edoxaban were associated with a lower risk of bleeding, though no significant difference in effectiveness was observed among all OACs.

About the authors

Siyu Yang

Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University,

Email: info@benthamscience.net

Ye Xu

Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University

Email: info@benthamscience.net

Yang Zhang

Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University

Email: info@benthamscience.net

Dandan Li

Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University

Author for correspondence.
Email: info@benthamscience.net

Xingang Li

Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University,

Author for correspondence.
Email: info@benthamscience.net

References

  1. Kuroda M, Tamiya E, Nose T, et al. Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation. JAMA Cardiol 2022; 7(6): 583-90. doi: 10.1001/jamacardio.2022.0480 PMID: 35416910
  2. Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145(4): 242-55. doi: 10.1161/CIRCULATIONAHA.121.056355 PMID: 34985309
  3. January CT, Wann LS, Calkins H. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 2019; 140(2): e125-52. doi: 10.1161/CIR.0000000000000665
  4. Wang X, Ma Y, Hui X, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Libr 2023; 2023(4): CD010956. doi: 10.1002/14651858.CD010956.pub3 PMID: 37058421
  5. Van der Linden L, Vanassche T, Van Cutsem E, Van Aelst L, Verhamme P. Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Br J Clin Pharmacol 2023; 89(8): 2369-76. doi: 10.1111/bcp.15785 PMID: 37170893
  6. Naung Tun H, Kyaw MT, Rafflenbeul E, López Suástegui X. Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis. Eur Cardiol 2022; 17: e11. doi: 10.15420/ecr.2021.55 PMID: 35620356
  7. Cohen AT, Sah J, Dhamane AD, et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost 2022; 122(6): 926-38. doi: 10.1055/s-0041-1740254 PMID: 34963185
  8. Pirmohamed M. Warfarin: Almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62(5): 509-11. doi: 10.1111/j.1365-2125.2006.02806.x PMID: 17061959
  9. Ferrari F, da Silveira AD, Martins VM, Franzoni LT, Zimerman LI, Stein R. Direct-acting oral anticoagulants in atrial fibrillation. Cardiol Rev 2021; 29(3): 120-30. doi: 10.1097/CRD.0000000000000312 PMID: 32332235
  10. Bovio JA, Smith SM, Gums JG. Dabigatran etexilate: A novel oral thrombin inhibitor for thromboembolic disease. Ann Pharmacother 2011; 45(5): 603-14. doi: 10.1345/aph.1P644 PMID: 21540406
  11. Roberti R, Iannone LF, Palleria C, et al. Direct oral anticoagulants: From randomized clinical trials to real-world clinical practice. Front Pharmacol 2021; 12: 684638. doi: 10.3389/fphar.2021.684638 PMID: 34122113
  12. Zhang Y, Souverein PC, Gardarsdottir H, van den Ham HA, Maitland-van der Zee AH, de Boer A. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. Br J Clin Pharmacol 2020; 86(6): 1150-64. doi: 10.1111/bcp.14227 PMID: 32022295
  13. Hindley B, Lip GYH, McCloskey AP, Penson PE. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opin Drug Metab Toxicol 2023; 19(12): 911-23. doi: 10.1080/17425255.2023.2287472 PMID: 37991392
  14. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41(4): 543-603. doi: 10.1093/eurheartj/ehz405 PMID: 31504429
  15. Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021; 61(1): 9-82. doi: 10.1016/j.ejvs.2020.09.023 PMID: 33334670
  16. Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: Evidence and unresolved issues. Lancet 2020; 396(10264): 1767-76. doi: 10.1016/S0140-6736(20)32439-9 PMID: 33248499
  17. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS). Eur Heart J 2021; 42(5): 373-498. doi: 10.1093/eurheartj/ehaa612 PMID: 32860505
  18. Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23(10): 1612-76. doi: 10.1093/europace/euab065 PMID: 33895845
  19. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE. Chest 2021; 160(6): e545-608. doi: 10.1016/j.chest.2021.07.055 PMID: 34352278
  20. Harrington J, Carnicelli AP, Hua K, et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF. Circulation 2023; 147(23): 1748-57. doi: 10.1161/CIRCULATIONAHA.122.062752 PMID: 37042255
  21. Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-drug interactions with direct oral anticoagulants. Clin Pharmacokinet 2020; 59(8): 967-80. doi: 10.1007/s40262-020-00879-x PMID: 32157630
  22. Mar PL, Gopinathannair R, Gengler BE, et al. Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol 2022; 15(6): e007956. doi: 10.1161/CIRCEP.121.007956 PMID: 35622425
  23. Hanigan S, Park JM. Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction. Expert Opin Drug Metab Toxicol 2022; 18(3): 1-14. doi: 10.1080/17425255.2022.2074397 PMID: 35543017
  24. Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): From pharmacological to clinical practice. Pharmaceutics 2022; 14(6): 1120. doi: 10.3390/pharmaceutics14061120 PMID: 35745692
  25. Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs 2019; 79(15): 1625-34. doi: 10.1007/s40265-019-01183-0 PMID: 31440911
  26. Grymonprez M, Vanspranghe K, Capiau A, Boussery K, Steurbaut S, Lahousse L. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis. Br J Clin Pharmacol 2022; 88(7): 3039-51. doi: 10.1111/bcp.15265 PMID: 35132677
  27. Grymonprez M, Vanspranghe K, Steurbaut S, De Backer TL, Lahousse L. Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation using P-gp and/or CYP450-interacting drugs: A systematic review and meta-analysis. Cardiovasc Drugs Ther 2023; 37(4): 781-91. doi: 10.1007/s10557-021-07279-8 PMID: 34637052
  28. Harskamp RE, Teichert M, Lucassen WAM, van Weert HCPM, Lopes RD. Impact of polypharmacy and P-Glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther 2019; 33(5): 615-23. doi: 10.1007/s10557-019-06907-8 PMID: 31520256
  29. Kim IS, Kim HJ, Yu HT, et al. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. J Cardiol 2019; 73(6): 515-21. doi: 10.1016/j.jjcc.2018.12.018 PMID: 30770140
  30. Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the issue of drug-drug interactions: From pharmacology to clinical practice. Drugs 2020; 80(11): 1065-83. doi: 10.1007/s40265-020-01328-6 PMID: 32504376
  31. Bezabhe WM, Bereznicki LR, Radford J, et al. Five-year trends in potential drug interactions with direct-acting oral anticoagulants in patients with atrial fibrillation: An australian-wide study. J Clin Med 2020; 9(11): 3568. doi: 10.3390/jcm9113568 PMID: 33167560
  32. Holt A, Strange JE, Rasmussen PV, et al. Bleeding risk following systemic fluconazole or topical azoles in patients with atrial fibrillation on apixaban, rivaroxaban, or dabigatran. Am J Med 2022; 135(5): 595-602.e5. doi: 10.1016/j.amjmed.2021.11.008 PMID: 34861201
  33. Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 2023; s-0043-s-1762596. doi: 10.1055/s-0043-1762596 PMID: 36731488
  34. Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: Potential implications on DOAC treatment. CNS Drugs 2023; 37(3): 203-14. doi: 10.1007/s40263-023-00990-0 PMID: 36869199
  35. Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: Nested case-control study. Clin Pharmacol Ther 2021; 110(6): 1526-36. doi: 10.1002/cpt.2369 PMID: 34287842
  36. Ngo LT, Yang S, Tran QT, Kim SK, Yun H, Chae J. Effects of carbamazepine and phenytoin on pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics 2020; 12(11): 1040. doi: 10.3390/pharmaceutics12111040 PMID: 33143037
  37. Wen HN, He QF, Xiang XQ, Jiao Z, Yu JG. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thromb Res 2022; 218: 24-34. doi: 10.1016/j.thromres.2022.08.007 PMID: 35985100
  38. Stöllberger C, Finsterer J. Update on drug interactions with non-vitamin-K-antagonist oral anticoagulants for stroke prevention in elderly patients. Expert Rev Clin Pharmacol 2021; 14(5): 569-81. doi: 10.1080/17512433.2021.1908124 PMID: 33757376
  39. Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 2020; 49(4): 636-43. doi: 10.1007/s11239-020-02037-3 PMID: 31925665
  40. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92. doi: 10.1056/NEJMoa1107039 PMID: 21870978
  41. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91. doi: 10.1056/NEJMoa1009638 PMID: 21830957
  42. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104. doi: 10.1056/NEJMoa1310907 PMID: 24251359
  43. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51. doi: 10.1056/NEJMoa0905561 PMID: 19717844
  44. Scaglione F. New oral anticoagulants: Comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013; 52(2): 69-82. doi: 10.1007/s40262-012-0030-9 PMID: 23292752
  45. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162(11): 777-84. doi: 10.7326/M14-2385 PMID: 26030634
  46. Higgins JPT, Altman DG, Gotzsche PC. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928. doi: 10.1136/bmj.d5928
  47. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol 2001; 54(10): 1046-55. doi: 10.1016/S0895-4356(01)00377-8 PMID: 11576817
  48. Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. J Am Coll Cardiol 2014; 64(15): 1541-50. doi: 10.1016/j.jacc.2014.07.967 PMID: 25301455
  49. Pham P, Schmidt S, Lesko L, Lip GYH, Brown JD. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020; 3(4): e203593. doi: 10.1001/jamanetworkopen.2020.3593 PMID: 32329770
  50. Holm J, Mannheimer B, Malmström RE, Eliasson E, Lindh JD. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol 2021; 77(3): 409-19. doi: 10.1007/s00228-020-03015-7 PMID: 33029651
  51. Xu Y, Chang AR, Inker LA, McAdams-DeMarco M, Grams ME, Shin JI. Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation. J Am Heart Assoc 2022; 11(14): e025723. doi: 10.1161/JAHA.122.025723 PMID: 35861836
  52. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: A subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015; 36(33): 2239-45. doi: 10.1093/eurheartj/ehv201 PMID: 25971288
  53. Bistervels IM, Bavalia R, Gebel M, et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. J Thromb Haemost 2022; 20(6): 1376-84. doi: 10.1111/jth.15692 PMID: 35253983
  54. Washam JB, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF trial). Am J Cardiol 2017; 120(4): 588-94. doi: 10.1016/j.amjcard.2017.05.026 PMID: 28645473
  55. Gandhi SK, Reiffel JA, Boiron R, Wieloch M. Risk of major bleeding in patients with atrial fibrillation taking dronedarone in combination with a direct acting oral anticoagulant (from a U.S. claims database). Am J Cardiol 2021; 159: 79-86. doi: 10.1016/j.amjcard.2021.08.015 PMID: 34656316
  56. Friberg L. Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol 2018; 264: 85-90. doi: 10.1016/j.ijcard.2018.02.055 PMID: 29776576
  57. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm 2014; 11(6): 925-32. doi: 10.1016/j.hrthm.2014.03.006 PMID: 24833235
  58. Wanat MA, Wang X, Paranjpe R, et al. Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study. Res Pract Thromb Haemost 2019; 3(4): 674-83. doi: 10.1002/rth2.12221 PMID: 31624787
  59. Grześk G, Rogowicz D, Wołowiec Ł, et al. The clinical significance of drug-food interactions of direct oral anticoagulants. Int J Mol Sci 2021; 22(16): 8531. doi: 10.3390/ijms22168531 PMID: 34445237
  60. Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 2017; 31(4): 193-203. doi: 10.1016/j.blre.2017.02.001 PMID: 28196633
  61. Desai J, Kolb J, Weitz J, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants - defining the issues and the management strategies. Thromb Haemost 2013; 110(8): 205-12. doi: 10.1160/TH13-02-0150 PMID: 23702623
  62. Oh HJ, Ryu KH, Park BJ, Yoon BH. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants. Medicine 2021; 100(11): e25216. doi: 10.1097/MD.0000000000025216 PMID: 33726018
  63. Gillis AM, Kates RE. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet 1984; 9(5): 375-403. doi: 10.2165/00003088-198409050-00001 PMID: 6437721
  64. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986; 11(6): 425-49. doi: 10.2165/00003088-198611060-00002 PMID: 3542336
  65. Dorian P. Clinical pharmacology of dronedarone: Implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15(4_suppl) (Suppl.): 15S-8S. doi: 10.1177/1074248410367792 PMID: 20472816
  66. Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013; 78(2): 227-39. doi: 10.1016/j.gie.2013.04.179 PMID: 23725876
  67. Yavuz B, Ayturk M, Ozkan S, et al. A real world data of dabigatran etexilate: Multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis 2016; 42(3): 399-404. doi: 10.1007/s11239-016-1361-4 PMID: 27085540
  68. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61(22): 2264-73. doi: 10.1016/j.jacc.2013.03.020 PMID: 23562920
  69. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123(21): 2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747 PMID: 21576658
  70. He Y, Wong ICK, Li X, et al. The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: A meta-analysis of observational studies. Br J Clin Pharmacol 2016; 82(1): 285-300. doi: 10.1111/bcp.12911 PMID: 26889922
  71. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11): 1954-63. doi: 10.3748/wjg.v23.i11.1954 PMID: 28373761
  72. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176(11): 1662-71. doi: 10.1001/jamainternmed.2016.5954 PMID: 27695821
  73. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: A large population-based study. Gastroenterology 2017; 152(5): 1014-1022.e1. doi: 10.1053/j.gastro.2016.12.018 PMID: 28043907
  74. Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf 2017; 16(6): 673-85. doi: 10.1080/14740338.2017.1325870 PMID: 28467190
  75. Lupercio F, Romero J, Peltzer B, et al. Efficacy and safety outcomes of direct oral anticoagulants and amiodarone in patients with atrial fibrillation. Am J Med 2018; 131(5): 573.e1-8. doi: 10.1016/j.amjmed.2017.11.047 PMID: 29274758
  76. Guo WQ, Chen XH, Tian XY, Li L. Differences in gastrointestinal safety profiles among novel oral anticoagulants: Evidence from a network meta-analysis. Clin Epidemiol 2019; 11: 911-21. doi: 10.2147/CLEP.S219335 PMID: 31632152
  77. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Circulation 2015; 132(3): 194-204. doi: 10.1161/CIRCULATIONAHA.114.013267 PMID: 25995317
  78. Wang CL, Wu VCC, Chang KH, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother 2020; 6(3): 147-54. doi: 10.1093/ehjcvp/pvz035 PMID: 31384926
  79. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318(13): 1250-9. doi: 10.1001/jama.2017.13883 PMID: 28973247
  80. Sandhu RK, Islam S, Dover DC, et al. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes 2022; 8(2): 195-201. doi: 10.1093/ehjqcco/qcab002 PMID: 33480405
  81. Ho CJ, Chen SH, Lin CH, Lu YT, Hsu CW, Tsai MH. Non-vitamin K oral anticoagulants and anti-seizure medications: A retrospective cohort study. Front Neurol 2021; 11: 588053. doi: 10.3389/fneur.2020.588053 PMID: 33732201
  82. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111(9): 4471-6. doi: 10.1182/blood-2007-11-123711 PMID: 18316627

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers